PODD
Insulet Corporation
NASDAQ · Healthcare · Medical - Devices · US
$147.48
−2.06%Aug 25, 2026, 07:57 UTC
Algert Global LLC increased its stake in Insulet Corporation by 75.7% during the second quarter, acquiring 62,277 additional shares, as disclosed in a 13F filing.
Source:Aug 20, 2026, 07:18 UTC
Aurora Investment Counsel purchased a new stake of 14,672 shares in Insulet Corporation, valued at approximately $2,234,000, as disclosed in a 13F filing.
Source:Aug 13, 2026, 18:40 UTC
A securities class action lawsuit was filed against Insulet Corporation alleging it misled investors about the safety and reliability of its insulin delivery products.
Source:Aug 6, 2026, 01:11 UTC
Insulet Corporation issued guidance for Q3 2026 and full-year 2026 revenue growth, while cutting full-year revenue expectations due to weaker Type 2 diabetes user retention.
Source:Aug 5, 2026, 11:00 UTC
Insulet Corporation reported its financial results for the second quarter ended June 30, 2026, with revenue of $801.7 million, up 23.5% year-over-year, exceeding its guidance range.
Aug 3, 2026, 08:37 UTC
A class action lawsuit was filed against Insulet Corporation for alleged violations of U.S. securities laws, and the DJS Law Group is reminding investors of the case.
Source:Jul 31, 2026, 07:08 UTC
A class action lawsuit was filed against Insulet Corporation for alleged securities law violations under the Securities Exchange Act of 1934.
Jul 24, 2026, 10:36 UTC
A class action lawsuit has been filed against Insulet Corporation and certain senior executives for securities fraud.
Jul 14, 2026, 07:00 UTC
Insulet Corporation announced a global partnership with Calm to provide emotional well-being resources for the diabetes community.
Source:Jul 12, 2026, 15:10 UTC
A securities class action lawsuit was filed against Insulet Corporation alleging securities fraud between February 21, 2025 and May 26, 2026.
Jul 6, 2026, 17:36 UTC
The U.S. Food and Drug Administration classified Insulet Corp.'s recall of certain Omnipod insulin delivery pods as a Class I recall, the most serious classification, due to risk of serious injury or death.
Source:Jun 25, 2026, 00:00 UTC
Jonathan J. Mazelsky was appointed as a Class II director of Insulet Corp, effective July 1, 2026.
Jun 8, 2026, 03:44 UTC
Insulet Corporation launched significant enhancements to its Omnipod 5 Automated Insulin Delivery System in the US, including a new 100 mg/dL Target Glucose option and integration with Abbott's FreeStyle Libre 3 Plus sensor.
Source:Jun 6, 2026, 12:00 UTC
Insulet Corporation reveals new data supporting its Omnipod 6 and fully closed-loop AID systems.
Source:Jun 3, 2026, 11:00 UTC
Insulet Corporation rolled out an enhanced Omnipod 5 algorithm in the U.S. and expanded its compatibility with Abbott's FreeStyle Libre 3 Plus sensor.
Source: